US FDA signs deal to advance regulatory science with Arkansas state

15 August 2011

An agreement to establish a virtual Center of Excellence for Regulatory Science was signed last week between the US Food and Drug Administration's National Center for Toxicological Research (NCTR) and the state of Arkansas.

The Memorandum of Understanding (MOU) is the first between the FDA and a state establishing a joint center to enhance regulatory science. It sets the framework for joint research, educational training, collaborations and outreach in support of the FDA's mission to protect and promote public health.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Biotechnology